Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
Big Ten Cancer Research Consortium
Bristol-Myers Squibb
Ossium Health, Inc.
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Fondazione Italiana Linfomi - ETS
M.D. Anderson Cancer Center
Acerta Pharma BV
University of Washington
GlaxoSmithKline
Takeda
Bristol-Myers Squibb
UNC Lineberger Comprehensive Cancer Center
Immunitas Therapeutics
National Institutes of Health Clinical Center (CC)
Emory University
University of Washington
AstraZeneca
Thomas Jefferson University
AIDS Malignancy Consortium